Press release
Castle’s Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025
Highlights from Castle’s DecisionDx-SCC poster will be shared in a special podium presentation during the Late Breakers 2025 session on Tuesday, Jan. 21,
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nHighlights from Castle’s DecisionDx-SCC poster will be shared in a special podium presentation during the Late Breakers 2025 session on Tuesday, Jan. 21, from 10:45-11:15 a.m. local time\n\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of tests for skin cancer, DecisionDx-SCC, DecisionDx®-Melanoma and MyPath® Melanoma, through poster presentations at the annual Maui Derm Hawaii meeting, being held Jan. 20-24, 2025, in Maui, Hawaii.\n\n\nThe Company’s poster on DecisionDx-SCC, which was selected as a “Late Breakers” top five finalist for the best poster Akamai Award, shares new data from a study involving Castle’s largest cohort of patients with cutaneous squamous cell carcinoma (SCC) to date (n=1,408). This study demonstrates improved risk stratification of patients with SCC tumors located on the head or neck when the test’s results are combined with Brigham and Women’s Hospital (BWH) staging.\n\n\n“Patients with SCC tumors of the head or neck may be at increased risk of metastasis and thus could be candidates for adjuvant treatments, such as radiation, to reduce this risk,” said Dr. Emily Ruiz, M.D., MPH, FAAD, board-certified dermatologist and Mohs micrographic surgeon at Brigham and Women’s Hospital in Boston, and Associate Professor of Dermatology at Harvard Medical School. “As demonstrated in the study, using the DecisionDx-SCC test alongside BWH staging improved the overall accuracy of metastatic risk predictions in patients with these higher-risk SCC tumors to further inform decisions that clinicians make with their patients regarding the appropriate treatment aligned to their risk of metastasis.”\n\n\nCastle’s posters at Maui Derm Hawaii, detailed below, will be available for viewing electronically on the conference app. Additionally, as a “Late Breaker” Five finalist, Castle’s DecisionDx-SCC poster will also be highlighted in a special podium presentation on Tuesday, Jan. 21, from 10:45-11:15 a.m. local time.\n\n\nDecisionDx-SCC\n\n\n\nTitle: Metastasis-free survival prediction with the 40-gene expression profile (40-GEP) test in patients with cutaneous squamous cell carcinoma of the head and neck (HNcSCC) risk stratified according to the Brigham and Wo...